One of the nation's top five hospitals, UCSF converts to Masimo SET pulse
oximetry and leverages revolutionary new noninvasive measurement capabilities
IRVINE, Calif., Feb. 13 /PRNewswire-FirstCall/ -- Masimo, the inventor of
Pulse CO-Oximetry and Measure-Through-Motion & Low Perfusion Pulse Oximetry,
today announced the completion of UCSF Medical Center's system-wide
implementation of Masimo SET pulse oximetry and the Masimo Rainbow SET
technology platform-establishing UCSF Medical Center as the first hospital to
implement Masimo Rainbow SET capabilities system-wide.
Initially, UCSF Medical Center performed an extensive pulse oximetry
comparison and thorough evaluation spanning virtually every department and
found that Masimo SET's obtained accurate and reliable oxygen saturation
measurements under difficult conditions, including patient motion and low
perfusion, as the chief reason for conversion to Masimo SET. Also, as part of
the evaluation, UCSF clinicians utilized new Masimo Rainbow SET technology to
noninvasively and continuously measure physiologic and hemodynamic components
that were previously only available by invasive tests. As a result, UCSF
decided to expand the adoption of Masimo technologies beyond pulse oximetry to
include the noninvasive patient monitoring capabilities of the Masimo Rainbow
SET technology platform.
UCSF Medical Center, a 600-bed hospital and academic medical center, is
among the top five hospitals in the nation according to U.S. News and World
Report. UCSF Medical Center, which also includes the 180-bed UCSF Children's
Hospital, Mount Zion for outpatient care and specialized programs, and more
than 60 outreach clinics, is also home to the only nationally-designated
Comprehensive Cancer Center and the only nationally designated Center of
Excellence in Women's Health in Northern California.
"Previously, low perfusion and patient motion were two of our toughest
challenges and the biggest obstacles to obtaining the accurate and reliable
SpO2 measurements we rely on to guide our treatment decisions," said Patricia
Roth, MD, Medical Director of Anesthesia Operating Room Support Services,
Associate Professor of Anesthesia & Perioperative Care, UCSF Medical Center,
San Francisco, California. "Masimo SET provides continuous, accurate oxygen
saturation measurements that reflect a patient's true status -- even during
low perfusion and motion. In addition, Masimo adhesive sensors have proven to
be more robust, allowing us to use just one sensor from Pre-Op, OR (Operating
Room) and PACU (Post-Anesthesia Care Unit) through to the general care floor
or ICU (Intensive Care Unit), while Masimo SET Perfusion Index (PI) and Pleth
Variability Index (PVI) measurements have exciting potential clinical
applications and added value."
In addition to their system-wide standardization on Masimo SET pulse
oximetry, UCSF also wanted to ensure that every site within their system was
Rainbow-enabled -- allowing UCSF clinicians to utilize advanced Masimo Rainbow
SET technology and revolutionary new noninvasive measurement capabilities
throughout their network facilities. Masimo Rainbow SET is an upgradable
noninvasive blood constituent monitoring platform capable of measuring blood
constituents that previously required invasive procedures. Masimo Rainbow
SET's first application is Pulse CO-Oximetry, the first and only technology
platform capable of continuously and noninvasively measuring Carboxyhemoglobin
(SpCO(TM)) and Methemoglobin (SpMet(TM)), in addition to Oxyhemoglobin (SpO2),
Perfusion Index (PI), Pleth Variability Index (PVI(TM)) and pulse rate.
By quickly and accurately determining levels of SpCO and SpMet -- two
critical dyshemoglobins proven to increase morbidity and mortality in a broad
range of clinical settings -- clinicians can accurately determine their
patients' true oxygenation status. PVI provides a continuous and noninvasive
quantified measurement of changes in the perfusion index that may compromise
cardiac function and affect systemic circulation, with potential clinical
applications for noninvasive hypovolemia detection and fluid responsiveness
monitoring. These new noninvasive measurement capabilities, unique to the
Masimo Rainbow SET technology platform, allow for more precise and timely
diagnosis and treatment.
Joe E. Kiani, CEO and Chairman of Masimo, stated; "UCSF Medical Center is
recognized throughout the world for offering pioneering treatments. From
becoming the first in the world to successfully perform surgery on a baby
still in the womb to developing life-saving treatments for premature infants
whose lungs aren't fully developed, UCSF is now pioneering the application of
new noninvasive measurements enabled by the Masimo Rainbow SET technology
platform to help advance the care they deliver now and into the future. This
combination of innovative medicine, advanced technology and compassionate care
is what makes UCSF a world leader in healthcare. We are proud of our
pioneering partnership with UCSF."
About Masimo
Masimo (Nasdaq: MASI) develops innovative monitoring technologies that
significantly improve patient care -- helping solve "unsolvable" problems. In
1995, the company debuted Measure-Through Motion and Low Perfusion pulse
oximetry, known as Masimo SET, and with it virtually eliminated false alarms
and increased pulse oximetry's ability to detect life-threatening events. More
than 100 independent and objective studies demonstrate that Masimo SET
provides the most trustworthy SpO2 and pulse rate measurements even under the
most difficult clinical conditions, including patient motion and low
peripheral perfusion. In 2005, Masimo introduced Masimo Rainbow SET, a
breakthrough noninvasive blood constituent monitoring platform that can
measure many blood constituents that previously required invasive procedures.
Rainbow SET continuously and noninvasively measures Carboxyhemoglobin
(SpCO(TM)) and Methemoglobin (SpMet(TM)), Pleth Variability Index (PVI(TM)),
in addition to Oxyhemoglobin (SpO2), Perfusion Index (PI) and pulse rate,
allowing early detection and treatment of potentially life-threatening
conditions. Founded in 1989, Masimo has the mission of "Improving Patient
Outcomes and Reducing Cost of Care by Taking Noninvasive Monitoring to New
Sites and Applications." Additional information about Masimo and its products
may be found at http://www.masimo.com.
Forward Looking Statements
This press release may include forward-looking statements. These
forward-looking statements are based on current expectations about future
events affecting us and are subject to uncertainties and factors, all of which
are difficult to predict and many of which are beyond our control, including:
risks related to our assumption that UCSF Medical Center's standardization to
Masimo technologies will serve to provide substantially increased revenues for
the company and risks related to our assumption that Masimo SET and Masimo
Rainbow SET will deliver a sufficient level of clinical improvement over
alternative pulse oximetry and patient monitoring systems to allow for rapid
adoption of the technology, as well as other factors discussed in the "Risk
Factors" section of our quarterly report on Form 10-Q for the quarter ended
September 29, 2007, filed with the Securities and Exchange Commission on
November 1, 2007. Although we believe that the expectations reflected in our
forward-looking statements are reasonable, we do not know whether our
expectations will prove correct. You are cautioned not to place undue reliance
on these forward-looking statements, which speak only as of the date hereof.
We do not undertake any obligation to update, amend or clarify these forward-
looking statements or the risk factors contained in our quarterly report on
Form 10-Q for the quarter ended September 29, 2007, whether as a result of new
information, future events or otherwise, except as may be required under the
federal securities laws.
Masimo, SET, Signal Extraction Technology, Improving Outcomes and Reducing
Cost of Care by Taking Noninvasive Monitoring to New Sites and Applications,
Rainbow, SpCO, SpMet, PVI and Pulse CO-Oximeter are trademarks or registered
trademarks of Masimo Corporation.
SOURCE Masimo Corporation
CONTACT: Dana Banks of Masimo Corporation, +1-949-297-7348
Web site: http://www.masimo.com